Filing Flows › Delcath Systems (DCTH) › Q1 2026 › vs Q1 2025
Delcath Systems (DCTH) Q1 2026 vs Q1 2025 (year over year)
Delcath Systems's revenue rose $5.2M (+26%) from $19.8M in Q1 2025 to $25.0M in Q1 2026. The biggest changes: HEPZATO KIT +$5.2M (+29%); CHEMOSAT −$14K (-0.8%).
Delcath Systems, Q1 2026: revenue $25.0M (+26% year over year), operating margin -6.5%, net loss $1.1M, operating cash flow $857K. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 1.1% | 10.4% | -9.3 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| HEPZATO KIT | $23.2M | $18.0M | $5.2M | +29% |
| CHEMOSAT | $1.7M | $1.8M | −$14K | -0.8% |
| Revenue | $25.0M | $19.8M | $5.2M | +26% |
| Other income, net | $729K | $622K | $107K | +17% |
| Net loss | $1.1M | −$1.1M | $2.1M | — |
| Costs & expenses | $26.8M | $20.4M | $6.4M | +31% |
| Operating costs | $26.6M | $19.1M | $7.5M | +39% |
| Income tax | $162K | $195K | −$33K | -17% |
| Cost of revenue | $3.7M | $2.8M | $891K | +31% |
| Research & development | $9.8M | $5.0M | $4.8M | +96% |
| SG&A | $13.1M | $11.3M | $1.8M | +16% |
| Operating cash sources | $5.0M | $6.9M | −$1.9M | -27% |
| Depreciation | $102K | $43K | $59K | +137% |
| Share-based compensation | $4.9M | $6.9M | −$1.9M | -28% |
| Net loss absorbed | $1.1M | −$1.1M | $2.1M | — |
| Working capital & other | $3.1M | $5.8M | −$2.7M | -46% |
| Operating cash flow | $857K | $2.2M | −$1.3M | -61% |
| Free cash flow (OCF − capex) | $287K | $2.1M | −$1.8M | -86% |
| Capital expenditures | $570K | $140K | $430K | +307% |
Questions
How much did Delcath Systems's revenue grow year over year in Q1 2026?
Delcath Systems's revenue rose $5.2M (+26%) from $19.8M in Q1 2025 to $25.0M in Q1 2026.
What drove Delcath Systems's revenue change in Q1 2026?
HEPZATO KIT +$5.2M (+29%); CHEMOSAT −$14K (-0.8%).